Must not be breastfeeding/lactating.
Breastfeeding should be discontinued
Lactating or breastfeeding women are excluded, breastfeeding should be discontinued prior to being treated with AZD1775; these potential risks may also apply to other agents used in this study
Breastfeeding
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Women who are breastfeeding and who are unwilling to stop breastfeeding prior to study entry
Inability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding; pregnant or breastfeeding women will be excluded from participation in this trial
Female patients who are breastfeeding; breastfeeding should be discontinued if the mother is treated with Pexa-Vec
Female patients who are pregnant or breastfeeding; breastfeeding should be discontinued
Not breastfeeding
Breastfeeding patients are ineligible
Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study
PHASE II: Women must not be pregnant or breastfeeding; breastfeeding must be discontinued or the subject is not eligible for the study
Breastfeeding should be discontinued
Breastfeeding
Breastfeeding
Pregnant or breastfeeding; breastfeeding may not resume for 14 days after the last dose of pazopanib
Not breastfeeding
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral tetrahydrouridine- decitabine [THU-Dec])
Participants who are breastfeeding are excluded
They are not breastfeeding;
Currently breastfeeding.
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excluded
Current breastfeeding
Breastfeeding
No breastfeeding
Breastfeeding
Participants who are breastfeeding are excluded
Breastfeeding
